Altered insulin-like grwoth factor binding proteins
AssigneeThe University of Adelaide
InventorBriony Forbes
Life of this patent
Estimating the term…
Abstract
Altered IGFBPs are able to bind IGF, but the release is inhibited by resistance to protease cleavage and/or reduced binding to extracellular matrix (ECM). Alterations have been made in IGFBP-2 to the linker domain in particular and to two amino acid motifs found to be important for ECM binding. IGF-1 mediated proliferation of cancer cells have been inhibited by use of the altered IGFBPs.
Claims41
An altered IGFBP-2 molecule able to effect binding of IGF-I or IGF-II with high affinity wherein an inhibited release of IGF occurs on contact with an extracellular matrix or exposure to a protease.
A nucleic acid encoding an altered IGFBP-2 molecule, said altered IGFBP molecule able to effect binding of IGF-I or IGF-II with high affinity wherein an inhibited release of IGF occurs on contact with an extracellular matrix or exposure to a protease.
Dependencies are inferred from the claim text.